Bayside Health
baysidehealth.org.auTotal trials
111
Active
1
Phase 3
10
Total enrollment
34,750
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tranexamic Acid 100Mg/ml Inj Vial 10ml | — | — | — | — | — | 1 |
Next readouts
- 2026-08-13
Top conditions
- HIV Infections6
- Cystic Fibrosis6
- Type 2 Diabetes5
- Schizophrenia4
- Cardiovascular Disease4
- Obesity4
- Coronary Artery Disease3
- Hepatitis C3
Frequently asked questions about Bayside Health
- How many clinical trials does Bayside Health have on ClinicalTrials.gov?
- Bayside Health is listed as the lead sponsor on 111 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bayside Health's trials are in Phase 3?
- 10 of Bayside Health's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Bayside Health focus on?
- Bayside Health's most-studied conditions on ClinicalTrials.gov are HIV Infections, Cystic Fibrosis, Type 2 Diabetes, Schizophrenia, Cardiovascular Disease.
- When are Bayside Health's next clinical trial readouts?
- Bayside Health has 1 upcoming primary-completion readout tracked here; the soonest is “Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial”, expected around 2026-08-13.